Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

With emerging research from The Sidney Kimmel Cancer Center-Jefferson Health, outcomes in patients with uveal melanoma that has metastasized were shown to significantly improve with changes in treatment.

In addition to safety and tolerability, a pair of clinical studies will evaluate the drug’s efficacy and ability to slow disease progression and to improve quality of life in patients with amyotrophic lateral sclerosis.

A study conducted by LSU Health found that by the time recommended screening for colorectal cancer begins, the disease has already spread in a high percentage of patients.

Top news from across the health care landscape.

Upadactinib met the primary endpoint for patients with active psoriatic arthritis who had responded inadequately or were intolerant to 1 or more non-biologic disease modifying anti-rheumatic drugs.

A new report from the Florida Pharmacy Association and American Pharmacy Cooperative, Inc, alleges that pharmacy benefit managers (PBMs) in the state are favoring their own affiliated pharmacies in the Florida Medicaid Program, both by driving customers to those pharmacies and by reimbursing them at higher rates.

As the industry focuses more on value-based care, predictive modeling allows pharmacies to shift their services from a one-size-fits-all approach to a personalized, high-touch strategy.

Top news of the day from across the health care landscape.

Several viable models continue to emerge for addressing the unique challenges of payment and financing for innovative, durable, curative gene and cell therapies.

Not only is cancer control a matter of public health, but its value should be viewed as an investment with considerable human and economic returns, according to a newly released report from the World Health Organization (WHO). Furthermore, although disparities between cancer care in lower- and higher-income countries may seem overwhelming, the report emphasized that they are entirely solvable with effective national cancer control plans.

Top news of the day from across the health care landscape.

The mechanism behind HIV resistance affects the ability of integrase strand transfer inhibitors to bind and block the HIV enzyme integrase.

Health systems, including inpatient and non-acute environments, will have a nearly 4% price increase for pharmaceutical purchases in the coming year, according to the report.

Top news of the day from across the health care landscape.

Canakinumab, a fully human monoclonal antibody, targets interleukin-1β, has anti-inflammatory effects, and is FDA-approved for rheumatologic disorders. Interleukein-1β is a cytokine that drives the interleukin(IL)-6 signaling pathway in inflammatory response.

Top news of the day from across the health care landscape.

As technology gains more of a foothold within the health care landscape, pharmacy professionals have an opportunity to harness the power of data and automatization.

Top news of the week from Specialty Pharmacy Times.

The decision is based on early academic clinical trial data that demonstrated ex-vivo autologous HSC gene therapy being an ideal approach for the treatment of X-CGD, a rare, life-threatening, inherited disease of the immune system.

Although there are no approved therapies for FSHD, researchers at Fulcrum Therapeutics discovered that inhibition of p38α/β reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD.

Some REMS programs may only require a medication guide to be distributed with each dispense that highlight safety information, such as relevant adverse events and risks associated with taking the product.

DSG3-CAART is designed to target the cause of mucosal pemphigus vulgaris while sparing normal B cell populations that provide immunity from infection.

Top news of the day from across the health care landscape.

Electronic health records and the data created are being used on multiple levels and continue to be a driving force for improving care and lowering health care costs.

Top news of the day from across the health care landscape.

A combination therapy may counter the resistance to human epidermal growth factor receptor 2 inhibitor neratinib in patients with breast, ovarian, lung, or other cancers.

Research may help to develop usable hematopoietic stem cells that could regrow a patient with leukemia’s blood system after chemotherapy and irradiation.